| Renal cell carcinoma | Nature Reviews Disease Primers | 2017 | 963 |
| The immune contexture in cancer prognosis and treatment | Nature Reviews Clinical Oncology | 2017 | 935 |
| Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma | Journal of Clinical Oncology | 2017 | 641 |
| First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study | Lancet, The | 2017 | 609 |
| Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study | JAMA Oncology | 2017 | 572 |
| P-Body Purification Reveals the Condensation of Repressed mRNA Regulons | Molecular Cell | 2017 | 332 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2017 | 328 |
| Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma | Annals of Oncology | 2017 | 324 |
| Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial | Journal of the National Cancer Institute | 2017 | 269 |
| Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial | Journal of Clinical Oncology | 2017 | 264 |
| Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma | Blood | 2017 | 201 |
| Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation | Gastroenterology | 2017 | 198 |
| What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis | Journal of Clinical Oncology | 2017 | 176 |
| Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA | Journal of Clinical Oncology | 2017 | 168 |
| Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group | Journal of Clinical Oncology | 2017 | 167 |
| The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients | European Urology | 2017 | 163 |
| Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma | Blood | 2017 | 156 |
| Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment | Annals of the Rheumatic Diseases | 2017 | 148 |
| The impact of replication stress on replication dynamics and DNA damage in vertebrate cells | Nature Reviews Genetics | 2017 | 140 |
| Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study | Annals of Oncology | 2017 | 129 |
| Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC | Journal of Hepatology | 2017 | 128 |
| Coffee Drinking and Mortality in 10 European Countries: A Multinational Cohort Study | Annals of Internal Medicine | 2017 | 127 |
| The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei | Histopathology | 2017 | 121 |
| Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis | European Journal of Cancer | 2017 | 110 |
| DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility | European Journal of Cancer | 2017 | 104 |
